{"doi":"10.1093/infdis/jiac188","title":"Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial","abstract":"BACKGROUND: Messenger RNA (mRNA)-1273 vaccine demonstrated 93.2% efficacy against coronavirus disease 2019 (COVID-19) in the Coronavirus Efficacy (COVE) trial. The humoral immunogenicity results are now reported. METHODS: Participants received 2 mRNA-1273 (100 µg) or placebo injections, 28 days apart. Immune responses were evaluated in a prespecified, randomly selected per-protocol immunogenicity population (n = 272 placebo; n = 1185 mRNA-1273). Serum binding antibodies (bAbs) and neutralizing antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-spike protein were assessed at days 1, 29, and 57 by baseline SARS-CoV-2-negative (n = 1197) and SARS-CoV-2-positive (n = 260) status, age, and sex. RESULTS: SARS-CoV-2-negative vaccinees had bAb geometric mean AU/mL levels of 35 753 at day 29 that increased to 316 448 at day 57 and nAb inhibitory dilution 50% titers of 55 at day 29 that rose to 1081 at day 57. In SARS-CoV-2-positive vacinees, the first mRNA-1273 injection elicited bAb and nAb levels that were 11-fold (410 049) and 27-fold (1479) higher than in SARS-CoV-2-negative vaccinees, respectively, and were comparable to levels after 2 injections in uninfected participants. Findings were generally consistent by age and sex. CONCLUSIONS: mRNA-1273 elicited robust serologic immune responses across age, sex, and SARS-CoV-2 status, consistent with its high COVID-19 efficacy. Higher immune responses in those previously infected support a booster-type effect. Clinical Trials Registration. NCT04470427.","journal":"The Journal of Infectious Diseases","year":2022,"id":254365,"datarank":0.6856205483358838,"base_score":3.091042453358316,"endowment":3.091042453358316,"self_citation_contribution":0.4636563680037475,"citation_network_contribution":0.22196418033213633,"self_endowment_contribution":0.4636563680037475,"citer_contribution":0.22196418033213633,"corpus_percentile":null,"corpus_rank":null,"citation_count":21,"citer_count":10,"citers_with_citation_signal":8,"citers_with_endowment":8,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8417,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04470427"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":3841,"name":"Lindsey R. Baden","orcid":null,"position":1,"is_corresponding":false},{"id":615313,"name":"Brandon Essink","orcid":"0000-0002-7309-228X","position":2,"is_corresponding":false},{"id":103755,"name":"David C. Montefiori","orcid":"0000-0003-0856-6319","position":3,"is_corresponding":false},{"id":901448,"name":"Adrian McDermont","orcid":null,"position":4,"is_corresponding":false},{"id":803915,"name":"Richard Rupp","orcid":"0000-0002-9659-1217","position":5,"is_corresponding":false},{"id":270693,"name":"Michael Lewis","orcid":"0000-0002-4958-6634","position":6,"is_corresponding":false},{"id":505154,"name":"Shobha Swaminathan","orcid":"0000-0001-8609-3073","position":7,"is_corresponding":false},{"id":901449,"name":"Carl Griffin","orcid":null,"position":8,"is_corresponding":false},{"id":901450,"name":"Veronica Fragoso","orcid":null,"position":9,"is_corresponding":false},{"id":901451,"name":"Vicki E. Miller","orcid":null,"position":10,"is_corresponding":false},{"id":900990,"name":"Bethany Girard","orcid":"0000-0001-9390-230X","position":11,"is_corresponding":false},{"id":901452,"name":"Yamuna Devi Paila","orcid":null,"position":12,"is_corresponding":false},{"id":615317,"name":"Weiping Deng","orcid":"0000-0002-9825-3297","position":13,"is_corresponding":false},{"id":615320,"name":"Joanne E. Tomassini","orcid":"0000-0002-9399-2867","position":14,"is_corresponding":false},{"id":593255,"name":"Robert Paris","orcid":"0000-0003-3234-5989","position":15,"is_corresponding":false},{"id":615319,"name":"F. Schödel","orcid":"0000-0002-4059-6289","position":16,"is_corresponding":false},{"id":900991,"name":"Rituparna Das","orcid":"0000-0002-5166-0311","position":17,"is_corresponding":false},{"id":615316,"name":"Allison August","orcid":"0000-0002-8668-5252","position":18,"is_corresponding":false},{"id":218082,"name":"Brett Leav","orcid":"0000-0003-0907-0817","position":19,"is_corresponding":false},{"id":615321,"name":"Jacqueline M. Miller","orcid":"0000-0002-7083-2182","position":20,"is_corresponding":false},{"id":98417,"name":"Honghong Zhou","orcid":null,"position":21,"is_corresponding":false},{"id":615318,"name":"Rolando Pajón","orcid":"0000-0002-5155-5079","position":22,"is_corresponding":false},{"id":901453,"name":"for the Coronavirus Efficacy (COVE) Study Group","orcid":null,"position":23,"is_corresponding":false},{"id":98392,"name":"Hana M. El Sahly","orcid":"0000-0003-0489-0074","position":0,"is_corresponding":true}],"reference_count":43,"raw_metadata":null,"created_at":"2026-07-19T00:25:03.918844Z","pmid":"35535503","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}